Allspring Global Investments
RIGL icon

Allspring Global Investments’s Rigel Pharmaceuticals RIGL Stock Holding History

Allspring Global Investments’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-119
Closed -$1.93K – 2273
2024
Q3 		$1.93K Buy
+119
New +$1.4K ﹤0.01% 2263
2023
Q4 		– Sell
-10,507
Closed -$113K – 2647
2023
Q3 		$113K Buy
10,507
+2,353
+29% +$28.3K ﹤0.01% 1950
2023
Q2 		$105K Sell
8,154
-685
-8% -$9.26K ﹤0.01% 2034
2023
Q1 		$117K Buy
8,839
+1,846
+26% +$29.3K ﹤0.01% 1991
2022
Q4 		$105K Buy
6,993
+3,499
+100% +$32.1K ﹤0.01% 2060
2022
Q3 		$41K Buy
3,494
+1,842
+112% +$24.9K ﹤0.01% 2424
2022
Q2 		$18K Sell
1,652
-23,060
-93% -$463K ﹤0.01% 2507
2022
Q1 		$738K Sell
24,712
-4,721
-16% -$128K ﹤0.01% 2053
2021
Q4 		$779K Buy
+29,433
New +$888K ﹤0.01% 2088

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allspring Global Investments's RIGL Position: Q4 2024 in Review

Allspring Global Investments sold out of Rigel Pharmaceuticals (RIGL) in Q4 2024, closing a stake of 119 shares — an estimated $1.93K sold.

Allspring Global Investments first reported a position in RIGL in Q4 2021 and held it in 9 quarters. The position peaked at $779K in Q4 2021. 122 funds tracked by Wall St. Rank hold RIGL as of Q4 2024.

  • Allspring Global Investments reported no remaining Rigel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 119 Rigel Pharmaceuticals shares in Q4 2024, an estimated $1.93K.
  • Allspring Global Investments first reported a position in Rigel Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Allspring Global Investments's Rigel Pharmaceuticals position peaked at $779K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.